A 52-week multicenter, randomized, double-masked, 2-arm parallel study to compare efficacy, safety and immunogenicity of SOK583A1 to Eylea, administered intravitreally, in patients with neovascular age-related macular degeneration.

Administered By

Awarded By

Contributors

Start/End

  • October 29, 2020 - March 6, 2023